Accendra Health (ACH)
Provides home medical equipment and supplies through Apria and Byram.
Something off on this page? Send us feedback.
Provides home-based care products, technology, and services through Apria and Byram, connecting patients, providers, and insurers beyond the hospital. Continuing operations are a single reporting segment shaped by diabetes, sleep therapy, respiratory therapy, ostomy, wound care, and urology categories.
Runs a home-based care platform built around Apria and Byram Healthcare. Apria focuses on durable medical equipment supplies and in-home clinical support for sleep apnea, respiratory care, and negative pressure wound therapy. Byram adds DME supplies and education for diabetes, urology, ostomy, wound care, incontinence, and breast pumps.
Connects patients, providers, and insurers with products, technology, and services that support health beyond the hospital. The business is run from Virginia and reflects the former Patient Direct platform after the hospital products and distribution business was sold.
Operates as one continuing reporting segment, with commercial payors, Medicare, and Medicaid shaping reimbursement. The mix depends on chronic-care categories and on payor contracts, including large commercial relationships.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | UBS | Reiterate | Rating: —Target: $4.50 | Target: $1.50 |
| Aug 11, 2026 | Robert W. Baird | Target | Target: $6 | Target: $1.50 |
| Aug 11, 2026 | Citigroup | Downgrade | ||
| Aug 10, 2026 | UBS | Upgrade | ||
| Aug 10, 2026 | Jefferies | Downgrade | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.7M · Total debt $1.78B · Total assets $2.11B · Shareholders' equity −$550.9M
- Revenue
- $613.2M
- Operating income
- −$35.2M
- Net income
- −$89.1M
HistoryDividendAnnual yield
| Institutions | 0.00% | 1 shares | |
|---|---|---|---|
| 1 holder · as of Jun 30, 2026 | |||
| Insiders | 9.37% | 7.20M shares | |
| 16 holders · as of May 20, 2026 | |||
| Strategic holders | 24.13% | 18.55M shares | |
| 2 holders · as of Oct 2, 2025 | |||
| Other | 66.50% | 51.15M shares | |
| remainder | |||
76.90M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Coliseum Capital Management, LLCStrategic10 percent owner | 17.04% | 13.10M | filed Aug 14, 2025 |
BlackRock, Inc.Strategic | 7.09% | 5.45M | filed Oct 2, 2025 |
Kevin M. WebbInsider | 5.57% | 4.29M | filed Mar 30, 2026 |
Edward A. PesickaInsiderdirector, officer: President & CEO | 1.39% | 1.07M | filed May 19, 2026 |
Perry A. BernocchiInsiderofficer: EVP, Chief Operating Officer | 0.41% | 313,913 | filed May 19, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- AdaptHealth
Broad HME rival across sleep, respiratory, diabetes, and home supplies
- Cardinal Health
At-home supply channel for diabetes, ostomy, urology, and wound care
- Linde
Public parent of Lincare, a large respiratory homecare provider
- Viemed Healthcare
Home respiratory and sleep-care peer with clinical support model
- Inogen
Respiratory device rival in oxygen therapy and homecare products
- CVS Health
PBM, retail-pharmacy, and home-care channel pressure
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Accendra Health | $0.7752 | −8.80% | $65.1M | — | — | 0.0 | −10.1% |
| AdaptHealth | $5.75 | −0.29% | $785.0M | — | — | 0.3 | −7.5% |
| Cardinal Health | $223.01 | +0.43% | $52.00B | 30.7 | 17.8 | 0.2 | +5.8% |
| Linde | $470.44 | +1.19% | $215.07B | 30.0 | 25.2 | 6.1 | +9.4% |
| Viemed Healthcare | $8.83 | −1.45% | $341.3M | 24.6 | 17.9 | 1.1 | +23.9% |
| Inogen | $5.06 | −3.35% | $141.6M | — | — | 0.4 | +3.0% |
| CVS Health | $86.03 | −1.23% | $111.13B | 23.0 | 10.6 | 0.3 | +7.3% |
| Median | 27.3 | 17.9 | 0.3 | +6.6% |